Understanding Enzyme Replacement Science: How Strensiq Improves Infant HPP Survivability

Understanding Enzyme Replacement Science: How Strensiq Improves Infant HPP Survivability

Hypophosphatasia (HPP) is a rare genetic disorder marked by low levels of tissue-nonspecific alkaline phosphatase (TNSALP). Infants with the most severe form often face life-threatening complications such as respiratory failure and impaired bone mineralization. Strensiq (asfotase alfa) is the first enzyme replacement therapy approved to address this root cause. Below, we explain how it works, review key data on Strensiq asfotase alfa survival rates, and outline what families can expect.

What Is Infantile Hypophosphatasia?

• Genetic mutation leads to deficient TNSALP activity.
• Low enzyme activity causes accumulation of substrates (e.g., inorganic pyrophosphate) that inhibit bone mineralization.
• Severe infantile HPP presents in the first six months with:
  • Poor bone development (rickets-like changes)
  • Muscle weakness
  • Respiratory complications due to chest wall abnormalities
  • High risk of premature death without treatment

How Strensiq (Asfotase Alfa) Works

Strensiq replaces the missing TNSALP enzyme. Its design includes:

• A human recombinant TNSALP core to restore enzyme activity.
• A deca-aspartate peptide that directs the enzyme to bone tissue.
• A constant region (Fc) that extends the enzyme’s presence in the bloodstream.

By delivering active TNSALP to bone surfaces, Strensiq:

1. Breaks down inorganic pyrophosphate.
2. Allows normal mineral deposition.
3. Improves bone strength and chest wall development.
4. Enhances muscle function and overall growth.

Clinical Evidence on Survival and Growth

Multiple clinical trials and real-world studies have evaluated Strensiq asfotase alfa survival rates and long-term outcomes in infants:

• Phase 2/3 Study (NCT01163149):
  • 69 infants with life-threatening HPP received Strensiq at birth or soon after diagnosis.
  • At 1 year, 95% of treated infants survived, compared to approximately 42% survival in a historical untreated cohort.
  • Respiratory support needs decreased significantly within months of starting therapy.

• Open-Label Extension (Up to 5 Years):
  • Continued improvements in motor function, bone radiographs, and pulmonary status.
  • Sustained 90%+ survival at 3 years in those who began therapy early.

• Real-World Registry Data:
  • Consistent survival benefits mirrored clinical trial findings.
  • Early treatment (within days or weeks of birth) correlated with better outcomes.

These data highlight that Strensiq asfotase alfa survival rates in infants with HPP far exceed historical expectations and fundamentally change the disease trajectory.

Benefits Beyond Survival

While prolonging life is critical, Strensiq also supports growth and development:

• Improved Bone Health:
  • Radiographic healing of rickets-like deformities.
  • Increased bone mineral density.

• Enhanced Motor Milestones:
  • Infants achieve milestones (sitting, standing, walking) closer to typical age ranges.
  • Reduced muscle weakness and fatigue.

• Reduced Respiratory Complications:
  • Less dependence on ventilators and supplemental oxygen.
  • Better chest wall mechanics.

• Quality of Life Gains:
  • Families report improved feeding, play activity, and social engagement.
  • Less hospital time and fewer invasive procedures.

Safety and Administration

Strensiq is given as a subcutaneous injection, typically three to six times per week, depending on weight and clinical response. Common side effects are generally mild to moderate:

• Injection site reactions (redness, swelling)
• Fever or irritability shortly after dosing
• Occasionally mild elevated calcium levels

Healthcare teams monitor:

• Growth parameters (weight, length/height)
• Radiographic bone healing
• Respiratory status and oxygen needs
• Laboratory values (alkaline phosphatase activity, calcium, vitamin D)

Close follow-up ensures that dosing adjustments address any emerging concerns.

Key Considerations for Families

1. Early Diagnosis Matters
   • The sooner treatment begins, the more pronounced the benefits.
   • Genetic testing and biochemical assays confirm the diagnosis.

2. Multidisciplinary Care
   • Coordination among metabolic specialists, pulmonologists, orthopedists, and physical therapists can optimize outcomes.

3. Ongoing Monitoring
   • Regular visits help track growth, bone health, and respiratory function.
   • Lab monitoring prevents and manages any metabolic imbalances.

4. Emotional and Practical Support
   • Connecting with patient advocacy groups can provide resources, community, and coping strategies.

Understanding Strensiq Asfotase Alfa Survival Rates

When searching for “Strensiq asfotase alfa survival rates,” you’ll find consistent evidence that early enzyme replacement fundamentally changes prognosis:

• Untreated infantile HPP historically had a survival rate below 50% at one year.
• With Strensiq, survival at one year exceeds 90%, and many infants reach normal childhood milestones.
• Long-term follow-up indicates maintained benefits in growth, bone health, and independence from respiratory support.

These numbers underscore that Strensiq asfotase alfa survival rates are among the most compelling data in rare disease enzyme therapy.

Next Steps: Recognize Symptoms Early

If your infant shows signs like:

• Unusually soft skull (craniotabes)
• Chest deformities or breathing difficulties
• Failure to thrive, feeding problems
• Delayed motor milestones

you might consider a free, online symptom check, using the doctor approved Ubie Symptom Checker. Assessing symptoms early can help you and your healthcare provider determine if further evaluation for HPP or other conditions is needed.

When to Speak to a Doctor

Always discuss any life-threatening or serious concerns with a qualified healthcare professional. If your child exhibits severe respiratory distress, profound skeletal abnormalities, or rapid health changes, seek medical attention immediately. Even milder symptoms warrant prompt evaluation to rule out HPP and start treatment as soon as possible.

---

Strensiq (asfotase alfa) represents a major advance for infants born with hypophosphatasia. By directly replacing the missing enzyme, it dramatically improves survival, bone health, and quality of life. Early recognition, diagnosis, and treatment are key. For personalized guidance, always rely on your medical team—and remember, in the face of serious or life-threatening symptoms, speak to a doctor right away.